Ultragenyx Pharma (RARE) Misses Q4 EPS by 3c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.75), $0.03 worse than the analyst estimate of ($1.72).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• NVE Corporation names new CEO and expands board to seven members